PSMA-11

• Product Name Alternative:

  HBED-CC-PSMA

• UNSPSC Description:

  PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer[1][2][3].

• Target Antigen:

  PSMA; Radionuclide-Drug Conjugates (RDCs)

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/psma-11.html

• Purity:

  99.74

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC(CN(CCN(CC(O)=O)CC1=CC(CCC(O)=O)=CC=C1O)CC2=CC(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=CC=C2O)=O

• Molecular Weight:

  946.99

• References & Citations:

  [1]Demirci E, et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun. 2016 Nov;37(11):1169-79.|[2]Eder M, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging[J]. Bioconjugate chemistry, 2012, 23(4): 688-697.|[3]Bois F, et al. [68Ga] Ga-PSMA-11 in prostate cancer: a comprehensive review[J]. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10(6): 349.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Clinical Information:

  Phase 3

• CAS Number:

  1366302-52-4